ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced that Roche is implementing a “three-pronged approach” to developing trastuzumab emtansine (T-DM1) for early stage HER2-positive breast cancer, according to plans outlined by Roche at its 2012 ASCO analyst event. Trastuzumab emtansine uses ImmunoGen’s TAP technology with Roche’s trastuzumab antibody and is in global development by Roche under an agreement between ImmunoGen and Genentech, a member of the Roche Group. In its analyst event presentation, Roche reported that it intends to initiate three studies with trastuzumab emtansine for early stage HER2-positive breast cancer, assessing the compound:
- As single-agent therapy for patients with residual invasive disease following preoperative (neoadjuvant) systemic treatment;
- Used in combination with chemotherapy and pertuzumab in the adjuvant setting; and
- Used in combination with chemotherapy and pertuzumab in the neoadjuvant setting.
About ImmunoGen, Inc.ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer cell-killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development with a wealth of clinical data reported. ImmunoGen’s collaborative partners include Amgen, Bayer HealthCare, Biotest, Lilly, Novartis, Roche and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com. This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including trastuzumab emtansine, including risks related to clinical studies and regulatory submissions, their timings and results. A review of these risks can be found in ImmunoGen’s Annual Report on Form 10-K for the fiscal year ended June 30, 2011 and other reports filed with the Securities and Exchange Commission.